$0.26
3.77%
Downside
Day's Volatility :10.64%
Upside
7.14%
48.46%
Downside
52 Weeks Volatility :91.13%
Upside
82.78%
Period | Brainstorm Cell Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -37.36% | 0.0% |
6 Months | -25.98% | 0.0% |
1 Year | -82.24% | 0.0% |
3 Years | -92.45% | -22.3% |
Market Capitalization | 22.6M |
Book Value | - $0.04 |
Earnings Per Share (EPS) | -0.2 |
PEG Ratio | 0.0 |
Wall Street Target Price | 3.46 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -178.2% |
Return On Equity TTM | -1121.9% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -16.0M |
Diluted Eps TTM | -0.2 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.18 |
EPS Estimate Next Year | -0.22 |
EPS Estimate Current Quarter | -0.03 |
EPS Estimate Next Quarter | -0.03 |
What analysts predicted
Upside of 1230.77%
Sell
Neutral
Buy
Brainstorm Cell Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Brainstorm Cell Therapeutics Inc | -6.33% | -25.98% | -82.24% | -92.45% | -93.59% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Brainstorm Cell Therapeutics Inc | NA | NA | 0.0 | -0.18 | -11.22 | -1.78 | NA | -0.04 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Brainstorm Cell Therapeutics Inc | Sell | $22.6M | -93.59% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Brainstorm Cell Therapeutics Inc
Revenue is up for the last 2 quarters, -569.0K → 365.0K (in $), with an average increase of 255.9% per quarter
Netprofit is up for the last 2 quarters, -3.40M → -2.54M (in $), with an average increase of 33.8% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 119.3%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 161.6%
Armistice Capital, LLC
Vanguard Group Inc
BlackRock Inc
Geode Capital Management, LLC
Liberty Wealth Management, LLC
Weaver Consulting Group
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Organization | Brainstorm Cell Therapeutics Inc |
Employees | 29 |
CEO | Mr. Chaim Lebovits |
Industry | Electronic Technology |
A Spac I Acquisition Corp
$0.26
-7.04%
Keyarch Acquisition Corp
$0.26
-7.04%
Connexa Sports Technologies Inc
$0.26
-7.04%
Us Value Etf
$0.26
-7.04%
First Wave Biopharma Inc
$0.26
-7.04%
Global X Msci Next Emerging
$0.26
-7.04%
Fat Projects Acquisition Corp
$0.26
-7.04%
Capital Link Global Fintech
$0.26
-7.04%
Applied Uv Inc
$0.26
-7.04%